Contextual differences considered in the Tunisian ADOLOPMENT of the European guidelines on breast cancer screening

Lara A. Kahale1, Hella Ouertatani2, Asma Ben Brahem2, Hela Grati2, Mohammed Ben Hamouda2, Zuleika Saz-Parkinson3 and Elie A. Akl1,4*

Abstract
Background: Breast cancer is a common disease in Tunisia and is associated with high mortality rates. The "Instance Nationale de l’Evaluation et de l’Accréditation en Santé" (INEAS) and the Tunisian Society of Oncology decided to develop practice guidelines on the subject. While the development of de novo guidelines on breast cancer screening is a demanding process, guideline adaptation appears more appropriate and context sensitive. The objective of this paper is to describe the adaptation process of the European Guidelines on Breast Cancer Screening and Diagnosis to the Tunisian setting in terms of the methodological process, contextual differences between the source and adoloped guideline, and changes in the recommendations.

Methods: We used the ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE)-ADOLOPMENT methodology to prioritize the topic, select the source guideline, and prioritize the questions and the outcomes. Once the source guideline was selected—the European Breast Cancer Guidelines—the European Commission´s Joint Research Centre shared with the project team in Tunisia all relevant documents and files. In parallel, the project team searched for local studies on the disease prevalence, associated outcomes' baseline risks, patients' values and preferences, cost, cost-effectiveness, acceptability, and feasibility. Then, the adoloping panel reviewed the GRADE evidence tables and the Evidence to Decision tables and discussed whether their own judgments were consistent with those from the source guideline or not. They based their judgments on the evidence on health effects, the contextual evidence, and their own experiences.

Results: The most relevant contextual differences between the source and adoloped guidelines were related to the perspective, scope, prioritized questions, rating of outcome importance, baseline risks, and indirectness of the evidence. The ADOLOPMENT process resulted in keeping 5 out of 6 recommendations unmodified. One recommendation addressing “screening versus no screening with ultrasound in women with high breast density on mammography screening” was modified from ‘conditional against’ to ‘conditional for either’ due to more favorable ratings by the adoloping panel in terms of equity and feasibility.

Conclusion: This process illustrates both the feasibility of GRADE-ADOLOPMENT approach and the importance of consideration of contextual evidence. It also highlights the value of collaboration with the organization that developed the source guideline.

*Correspondence: ea32@aub.edu.lb  
1 American University of Beirut, Beirut, Lebanon  
Full list of author information is available at the end of the article
Key words: Practice guideline, Adaptation, GRADE, Evidence-based medicine, Tunisia, Breast cancer, European Commission Initiative, ADOLOPMENT

Background
Breast cancer represents the second most prevalent cancer in the world affecting 2.1 million women each year [1]. According to the latest ‘Global Cancer Incidence, Mortality and Prevalence’ (GLOBOCAN) estimates, the incidence has increased by more than 20% and mortality by 14% in 4 years. The incidence rates are higher in the most developed countries, but mortality rates remain much higher in low-income countries, reflecting a gap in the early detection and access to treatment. In Tunisia, it represents the most common type of cancer; among 100,000 women, there are 32.2 incident cases and 10.3 related deaths each year [1].

To address this public health problem, the “Instance Nationale de l’Evaluation et de l’Accréditation en Santé” (INEAS) and the Tunisian Society of Oncology decided to develop practice guidelines on the subject. Indeed, guidelines can enhance evidence-based practice and reduce variability in practice [2].

However, developing guideline de novo (i.e., ‘from scratch’) can be a demanding process in terms of time, human, and financial resources. Alternative options to de novo development include adopting or adapting guidelines developed by others [3, 4]. While adoption of a guideline can be done quickly and with fewer resources, it might be inappropriate when contextual differences between the original and target setting exist. In these cases, adaptation of guidelines is a more appropriate approach as it takes into account contextual differences [4].

A methodological survey identified eight methodologies for the adaptation of health guidelines [4]. The ‘Grading of Recommendations Assessment, Development and Evaluation’ (GRADE)-ADOLOPMENT, one of these methodologies, combines the advantages of adoption, adaptation and de novo guideline development which allows the creation of recommendations appropriate to the context [3]. GRADE-ADOLOPMENT is based on three cornerstones: (1) identifying and prioritizing credible existing relevant guidelines or evidence syntheses (2) evaluating and completing the GRADE Evidence to Decision (EtD) frameworks for each of the recommendations; and (3) deciding on a final adoption, adaptation or de novo development for each of the recommendations [5].

The objective of this paper is to describe the project in terms of the methodological process, contextual differences between the source and adapted guideline, and changes in the recommendations.

Methods
Overall process
The process of this project is based on the steps of the Guidelines 2.0 checklist [6], and the GRADE-ADOLOPMENT approach [3]. We used the GRADEpro ‘guideline development tool (GDT) software [7] to develop GRADE evidence tables and EtD frameworks [5]. The GRADE evidence table provides the effect estimates for each outcome of interest and the associated certainty of evidence [8].

The EtD table includes information on the following criteria: desirable and undesirable effects, certainty of evidence, certainty about or variability in values and preferences, cost, and cost-effectiveness, equity, feasibility,
and acceptability [9–11]. The information included for each EtD criterion consists of judgment, research evidence, and additional considerations. Figure 1 shows this information displayed in columns for one of the factors (cost effectiveness used as an illustrative example) [12].

We describe below the methodological aspects of the project most relevant to the ADOLOPMENT process.

Contributors
INEAS is an independent public authority that contributes to the regulation of the health system in Tunisia through quality and efficiency. The guideline project was a collaborative effort between INEAS and the Tunisian Society of Oncology. The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH funded the study, while the ‘American University of Beirut’ (AUB) GRADE (Grading of Recommendations Assessment, Development and Evaluation) center provided the methodological support.

Two major groups were involved: the project team and the guideline panel. The project team consisted of four members from INEAS (ABB, HO, HG, MH) and two members of the AUB GRADE center (LK, EA). The guideline panel consisted of 12 local experts including medical and surgical oncologists, gynecologists, family medicine, radiologists, guideline methodologists, and governmental representatives. None of the panelists had financial conflict of interest.

Prioritization of the topic
The project team initially considered the following four topics: breast cancer screening, colorectal cancer screening, hypertension, and management of pain. The team then conducted a priority setting exercise to prioritize one of those topics [13, 14]. The factors considered for priority setting included: public health burden; avoidable mortality and morbidity; economic burden on the health care system and patient; emerging diseases or emerging care options; potential impact of intervention on health outcomes, economy, health care system, and equity; variation in clinical practice; and rapidly changing evidence [13, 14]. Eventually, the project team prioritized the topic of breast cancer screening as it was rated the highest.

Selection of the source guideline
The project team systematically searched for existing guidelines on breast cancer screening published after 2016, to ensure they were up to date. The group searched MEDLINE, GuidelineCentral, Guideline International Network database, and websites of guideline producing agencies such as the National Institute for Health and Care Excellence, National Comprehensive Cancer Network, Scottish Intercollegiate Guidelines Network, World Health Organization (WHO), Belgian Health Care Knowledge Center, and Agency for Healthcare Research and Quality.

The search identified 124 unique citations. The title and abstract screening yielded seven citations as potentially eligible (on breast cancer). The full-text screening of the seven citations identified two relevant guidelines that were based on systematic reviews and developed using the GRADE approach [15, 16]. Two members from INEAS (HO, ABB) independently assessed the methodological rigor and transparency of each of the two guidelines using the AGREE II tool [17]. The project team selected the breast cancer screening guidelines developed by the European Commission Initiative on Breast Cancer (ECIBC) as it scored the highest on the ‘Appraisal of Guidelines for Research and Evaluation’ (AGREE) II tool as shown in Fig. 2. [18].

**Fig. 2** Scoring of the two potentially eligible guidelines as per the AGREE II tool. WHO: World Health Organization, ECIBC: European Commission Initiative on Breast Cancer
Prioritization of questions and outcomes
For prioritizing the questions and the outcomes, the project team organized a face-to-face panel meeting in September 2018. The panelists anonymously rated the importance of each of the nine screening questions addressed in the source guideline at the time this ADOLPMENT process was started. They used a scale of 1–9 (least important—most important) and considered the relevance of the populations and interventions addressed by each question. Then, the panel discussed the rating results and selected the final set of questions through consensus.

Similarly, the panel rated the importance of the outcomes defined in each of the questions of the source guideline on a scale of 1–9 (7–9 indicates outcome is critical for decision-making, 4–6 indicates it is important, and 1–3 indicates it is not important for decision-making) [6].

Gathering the evidence and preparing the EtD
For the evidence on health effects, the ECIBC team (ZSP) shared with the project team the evidence syntheses reports and other relevant documents from the source guideline, including the GRADEpro files for GRADE evidence tables and EtD frameworks. Updating the search for the health effects evidence was not required to identify new evidence given the short timeline between the publication of the source guidelines and the ADOLPMENT process by the Tunisian panel.

For the contextual evidence, the project team searched for local studies on the disease prevalence, associated outcomes’ baseline risks, patients’ values and preferences, cost, cost-effectiveness, acceptability, and feasibility. As the team did not identify much of the needed data from published studies, it solicited them from panel members and searched for studies from contexts similar to that of Tunisia (i.e., Arabic countries of North African countries). The local baseline risk was integrated in the evidence summary tables. Then we adapted the standard EtD table in GRADEpro to use in the ADOLPMENT process, as the GRADEpro-GDT ADOLPMENT module had not been developed at that point. For each criterion we reproduced the ‘research evidence’, the ‘additional considerations’, and the ‘judgments’ from the source guideline. In addition, we added under ‘research evidence’ any identified local data (Fig. 3).

Finalizing the recommendations
In December 2018, the panel reviewed the GRADE evidence tables and the EtD frameworks. For each healthcare question, and for each EtD criterion, the panel started by reviewing the ‘research evidence’, the ‘additional considerations’, and the ‘judgments’ from the source guideline, as well as any identified ‘research evidence’ from the Tunisian setting. Next, they added their own ‘additional considerations’ for each criterion and discussed whether they would modify the judgments from the source guideline (Fig. 3). After going through all the criteria, they considered how the corresponding judgments were modified, and accordingly decided whether to modify the source recommendation and the accompanying remarks.

Results
Contextual differences between source and adoloped guidelines
We present in Table 1 below the most relevant contextual differences between the source and ADOLPMENT

![Fig. 3 Display of the standard EtD table adapted for use in the Tunisian ADOLPMENT project](image-url)
Table 1  Contextual differences between the source (ECIBC) and adoloped (Tunisian) guidelines

| Guideline Item          | ECIBC Guideline                        | Tunisian Guideline                     | Rationale for change by Tunisian panel                                                                 |
|-------------------------|----------------------------------------|----------------------------------------|------------------------------------------------------------------------------------------------------|
| Perspective             | Population                             | Individual                             | Organized mammography screening programs not available in Tunisia                                     |
| Scope                   | Screening and diagnosis                 | Screening                              | Feasibility considerations; first ADOLOPMENT experience                                              |
| Prioritized questions   | 9*                                      | 6                                      | 3 questions on screening using tomosynthesis were dropped, as tomosynthesis is not used in Tunisia as a screening tool |
| Rating of outcome importance | ‘All-cause mortality’ important; ‘overdiagnosis’ critical | ‘All-cause mortality’ not important; ‘overdiagnosis’ important | Change in perspective (from population to individual)                                                   |
| Baseline risks          | Breast Cancer incidence and breast cancer mortality rate from the meta-analysis control arm data | Lower breast cancer incidence, higher breast cancer mortality rate | Overall, the baseline risk of breast cancer mortality in Tunisia was assumed to be similar to that in Europe |
| Indirectness of the evidence | Judgment of indirectness made in the source guideline | Judgment of no (further) rating down of certainty of evidence for indirectness | Based on the consideration of how the characteristics of the populations or the interventions in the Tunisian setting compare to the setting of the source guideline |

*By the time the ADOLOPMENT process was initiated, the source guideline had published recommendations for nine questions only*
guidelines: perspective, scope, prioritized questions, rating of outcome importance, baseline risks, and indirectness of the evidence.

Changes in the recommendations
Figure 4 indicates whether the judgments made by the source panel were modified by the adoloping panel for the different EtD criterion and the recommendation statements, for each of the six questions. The ADOLPMENT process resulted in keeping 5 out of 6 recommendations unmodified. The modified recommendation addressed “screening versus no screening with ultrasound in women with high breast density on mammography screening”. The panel modified the recommendation from ‘conditional against’ to ‘conditional for either’ due to more favorable ratings by the adoloping panel in terms of equity and feasibility. For each of the five remaining unmodified recommendations, the adoloping panel had different judgments (relative to the source guideline) for at least one of the EtD criteria (range 2–4 criteria).

Discussion
Summary
The ADOLPMENT of the European Guidelines on Breast Cancer Screening and Diagnosis to the Tunisian setting illustrates the feasibility of carrying out this process with limited resources and in a short period of time (3 months). We have highlighted the complete methodological process followed which led to six contextual differences between the source guideline and the Tunisian one, and changes in the recommendations.

Facilitators and implementation considerations
A major facilitator to this ADOLPMENT project was the collaboration between the two teams of the source and ADOLPMENT guidelines. The ECIBC guideline project team allowed the unrestricted use of their recently published guideline and related material as the basis for the ADOLPMENT process [18]. Another major facilitator is the fact that the two guideline efforts used the same methodology (i.e., GRADE), and the same tools (e.g., RevMan, GRADEPro-GDT). On the other hand, one major challenge was the lack of published local evidence from Tunisia for values and preferences, and economic implications. The judgments made for those criteria relied mainly on expert evidence provided by the panelists [19].

A clear advantage of guideline adaptation is the ability to present the adoloping panel with evidence that has already been synthesized for the source guideline. However, it is not clear whether the panel should be also presented with the EtD sections completed by the source

Table 2 Three possible approaches to sharing with the adoloping panel information from the source guideline

| Approach | Contextual evidence | Information from the source guideline |
|----------|---------------------|---------------------------------------|
|          |                     | For each EtD criterion                |
|          |                     | Synthesized evidence | Judgment | Additional considerations | Recommendation |
| A        | x                   | x                                    | x        | x                      | x             |
| B        | x                   | x                                    | x        | x                      |               |
| C        | x                   | x                                    |          |                        |               |

Fig. 4 Changes made by the adoloping panel to the judgments made by the source guideline panel for the different EtD criteria and the recommendation statements, for each of the six questions. Rec: Recommendation. The blue shade refers to the changes made by the adoloping panel to the judgments made by the source guideline panel for the different EtD criterion and the recommendation statements, for each of the six questions. + refers to the change in judgment that made the corresponding factor more favorable. — refers to the change in judgment that made the corresponding factor less favorable.
guideline’ panel. These sections include ‘judgments’ and ‘additional considerations’ made for the different EtD criteria, and the final ‘recommendation’. In principle, there are three possible approaches to sharing information from the source guideline with the adoloping panel, as illustrated in Table 2.

Approach A would allow the panel to build on the source guideline’s full information and decide whether to modify any of the judgments or recommendation. Approach B would allow the panel to build on the source guideline’s information except for the recommendation. The panel would decide whether to modify any of the judgments but develop the recommendation independently. Approach C would allow the panel to make their judgments and develop the recommendations independently, taking into account only the evidence synthesized for the source guideline and the contextual evidence. This approach C would require more extensive discussions and time compared with the two other approaches. It could be used in scenarios when judgments and additional considerations are not available, when there are concerns about the judgments made by the source panel, and when preferred by the adoloping panel.

While we have used approach C in previous ADOLOPMENT projects [20–25], we opted to go for approach B in this project. The decision was driven by the preference of the adoloping panel, and by the scarcity of local evidence from Tunisia. These experiences and the principles for ADOLOPMENT [3] formed the basis for the development of the GRADEpro-GDT ADOLOPMENT module [7] which includes the following:

1. for each EtD criterion, the synthesized evidence on health effects, judgments, and additional considerations already made by the source guideline panel (reproduced from the source guideline);
2. for each EtD criterion, the contextual evidence, judgments, and additional considerations, to be made by the ADOLOPMENT guideline panel;
3. the recommendation developed by the source guideline panel (reproduced from the source guideline);
4. the recommendation to be developed by the adoloping panel.

However, including the elements from the source guideline (#1 and #3 above) are optional to allow the panelists select one of the three approaches discussed above (Table 2).

The information from the source guideline is reproduced but not editable. For the adoloped guideline, a blank section allows the project team to add any local evidence, and the adoloping panelists to include their own judgments, their own additional considerations, and their own recommendation. Figure 5 shows how the EtD used in this project (Fig. 3) would look using the GRADEpro-GDT ADOLOPMENT module. Figure 6 shows how the summary of the judgments across all criteria by both the source and the adoloped panels would look using the GRADEpro-GDT ADOLOPMENT module.

Implications for practice
This project illustrates a number of facilitators for guideline ADOLOPMENT, including (1) collaboration with the organization that developed the source guideline; (2) same methodology (GRADE) used for the source

---

**Cost effectiveness**

| JUDGMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |
|----------|-------------------|---------------------------|
| ○ Favors the comparison | Arrosipide et al found that the screening programme during the 15-year period for women aged 50 to 69 is related to an Incremental Cost-Effectiveness Ratio (ICER) below the threshold of €190 000 per Quality Adjusted Life Year (QALY). The programme proved to be cost-effective during the evaluation phase (Arrosipide 2016). | Cost-effectiveness probably favours the intervention in different countries or settings but varies across them. |
| ○ Probably favors the comparison | ○ Does not favor either the intervention or the comparison |
| ○ Probably favors the intervention | ○ Favors the intervention |
| ○ Varies | ○ No included studies |

Adolopment

| JUDGMENT | RESEARCH EVIDENCE | ADDITIONAL CONSIDERATIONS |
|----------|-------------------|---------------------------|
| ○ Favors the comparison | Additional local evidence identified: Une faible rentabilité en Tunisie du dépistage de masse du cancer du sein par la mammographie. Le nombre d’années de vie sauvees grâce à un programme de dépistage de masse par mammographie serait de 2.97 années de vie sauvées pour 1000 femmes; alors qu’il est de 16.55 en Grande Bretagne et 8.23 en Espagne. Il est de 3.2 ans en Finlande (étude ONFP Ariana) | Le PIB Tunisien est estimé à 3490 USD; Selon l’OMS l’ICER devrait être évalué à 3 fois le PIB, à savoir 10470 USD; En Europe avec un ICER de 10826 l’intervention est considérée non-coût-efficace. Les années de vie sauvées par cette intervention sont basses. On n’a pas de cout précis pour notre contexte. |
| ○ Probably favors the comparison | ○ Does not favor either the intervention or the comparison |
| ○ Probably favors the intervention | ○ Favors the intervention |
| ○ Varies | ○ No included studies |

---

Fig. 5 Display of how the EtD used in the Tunisian ADOLOPMENT would look using the GRADEpro-GDT ADOLOPMENT module
guideline development and the adoloped guideline; (3) availability of contextual evidence; (4) availability of an adaptation module in a guideline development tool (e.g., GRADEPro-GDT); and (5) engagement of panelists in the ADOLOPMENT process.

An organization aiming to facilitate the adaptation of its recommendations need to strategically optimize their ‘adaptability’. This can be achieved through using structured methodology, such as GRADE, making explicit detailed judgments related to the certainty of evidence and strength of recommendation. Such a methodology would also allow the presentation and judgment of the health effects and of the contextual factors separately, as the latter are more likely to be judged differently during the adaptation process. Providing open access to all relevant material (e.g., evidence syntheses, EtD tables) would also optimize adaptability of recommendations.

**Implications for research**

As illustrated by Fig. 4, the adoloping panel might change several judgments for some EtD criteria, without leading to a change in the recommendation. It would be interesting to explore to what extent this observation applies to other guideline adaptation efforts. In addition, there is a need to evaluate the feasibility of the three approaches of sharing with the adoloping panel information from the source guideline, and their acceptability by the panelists and methodologists. Finally, it would be helpful to develop an extension to the G-I-N-McMaster checklist for guideline development [6], to support groups adapting guidelines. [26] Of similar importance is the development of an extension of the RIGHT statement to improve the reporting of adapted guidelines. [27, 28]

**Conclusion**

This process illustrates both the feasibility of GRADE-ADOLOPMENT approach and the importance of consideration of contextual evidence. It also highlights the value of collaboration with the organization that developed the source guideline.

**Abbreviations**

AGREE: Appraisal of Guidelines for Research and Evaluation; AUB: American University of Beirut; ECIBC: European Commission Initiative on Breast Cancer; EtD: Evidence to decision; GIZ: Deutsche Gesellschaft für Internationale Zusammenarbeit; GLOBOCAN: Global Cancer Incidence, Mortality and Prevalence; GRADE: Grading of Recommendations Assessment, Development and Evaluation; INEAS: Instance Nationale de l’Evaluation et de l’Accréditation en Santé; WHO: World Health Organization.

**Acknowledgements**

The authors would like to acknowledge Pablo Alonso-Coello, Carlos Canelo, Monica Ballesteros, and David Rigau Comas from Iberoamerican Cochrane Center who were part of the systematic review team of the European Commission Initiative on Breast Cancer.

**Authors’ contributions**

LAK: conception and design, methodological support, data analysis and interpretation, drafting the article. HO: data acquisition, critical revision of the article for important intellectual content. ABB: data acquisition, critical revision of the article for important intellectual content. HG: data acquisition, critical revision of the article for important intellectual content. MBH: data acquisition, critical revision of the article for important intellectual content. ZS-P: data interpretation, critical revision of the article for important intellectual content. EAA: conception and design, methodological support, data analysis and interpretation, drafting the article. All authors read and approved the final manuscript.

**Funding**

The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH played no role in design of the study and collection, analysis, and interpretation of data or in writing the manuscript.

**Availability of data and materials**

Available upon request.
Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors report intellectual conflict of interest being members of the GRADE working group (LAK, EAA).

Author details
1 American University of Beirut, Beirut, Lebanon. 2 L’Instance Nationale de l’Evaluation et de l’Accréditation en Santé (INEAS), Tunis, Tunisia. 3 European Commission, Joint Research Centre, Ispra, Italy. 4 McMaster University, Hamilton, Canada.

Received: 3 September 2020   Accepted: 30 April 2021

References

1. Ferlay J, et al. Global and regional estimates of the incidence and mortality for 38 cancers: GLOBOCAN 2018. Lyon: International Agency for Research on Cancer. World Health Organization, 2018: p. 394–424.

2. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical practice guidelines we can trust. 2011. Washington, DC: National Academies Press.

3. Schünemann HJ, et al. GRADE Evidence to Decision (EtD) frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89–98.

4. Schünemann HJ, et al. A methodological survey identified eight proposed frameworks for the adaptation of health related guidelines. J Clin Epidemiol. 2017;86:3–10.

5. Schünemann HJ, et al. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. J Clin Epidemiol. 2016;76:89–98.

6. Schünemann HJ, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Can Med Assoc J. 2014;186(3):E123–42.

7. GRADEpro GDT, GRADEpro Guideline Development Tool (Software). 2015, McMaster University (developed by Evidence Prime, Inc.). gradepro.org.

8. Guyatt GH, et al. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311–6.

9. Alonso-Coello P, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed health-care choices. 2. Clinical practice guidelines. BMJ. 2016;353:i2089.

10. Alonso-Coello P, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed health-care choices. 1: Introduction. BMJ. 2016;353:i2089.

11. Moberg J, et al. The GRADE Evidence to Decision (EtD) framework for health system and public health decisions. Health Res Policy Syst. 2018;16(1):45.

12. European Commission. European Commission Initiative on Breast Cancer. https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines. 2020.

13. El-Harakeh A, et al. Prioritization approaches in the development of health practice guidelines: a systematic review. BMC Health Serv Res. 2019;19(1):692.

14. El-Harakeh A, et al. The implementation of prioritization exercises in the development and update of health practice guidelines: a scoping review. PLoS ONE. 2020;15(3):e0229249.

15. Schünemann HJ, et al. Methods for development of the European Commission initiative on breast cancer guidelines: recommendations in the era of guideline transparency. Ann Intern Med. 2019;171(4):273–80.

16. World Health Organization. WHO position paper on mammography screening. 2014: World Health Organization.

17. Brouwers MC, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839–42.

18. European Commission Initiative on Breast Cancer (ECIBC). Recommendations from European Breast Guidelines. https://ecbc.jrc.ec.europa.eu/recommendations/. 2019.

19. Schünemann HJ, Zhang Y, Oxman AD. Distinguishing opinion from evidence in guidelines. BMJ. 2019;366:l4606.

20. Arayssi T, et al. Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adopment of the 2015 American College of Rheumatology guidelines. Clin Rheumatol. 2018;37(11):2947–59.

21. Darzi A, et al. Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health Qual Life Outcomes. 2017;15(1):183.

22. Al‑Hameed F, et al. Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline. Ann Saudi Med. 2015;35(2):95–106.

23. Al‑Hameed FM, et al. The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in medical and critically ill patients. Saudi Med J. 2016;37(11):1279–93.

24. Al‑Hameed FM, et al. The Saudi clinical practice guideline for the prophylaxis of venous thromboembolism in medical and critically ill patients. Saudi Med J. 2015;36(8):1004–10.

25. Abdul‑Khalek RA, et al. Methods used in adaptation of health‑related guidelines: a systematic survey. J Glob Health. 2017;7(2):020412.

26. Song Y, et al. Extending the RIGHT statement for reporting adapted practice guidelines: a systematic survey. J Glob Health. 2019;9(9):e031767.

27. Song Y, et al. Extending the RIGHT statement for reporting adapted practice guidelines: a systematic survey. J Glob Health. 2019;9(9):e031767.

28. Goldah MW, et al. A very low number of national adaptations of the World Health Organization guidelines for HIV and tuberculosis reported their processes. J Clin Epidemiol. 2016;80:50–6.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.